There are more options than ever for colon-cancer screening. But this writer found out firsthand why the office visit is still best.
Looking back, I can see that I had some symptoms, but they were all things that were easy to brush off as something minor.
Rising diagnosed prevalence (about 170,000 US cases in 2025), wider JAK2/CALR molecular testing and the 2026 FDA approval of ropeginterferon alfa-2b drive growth in ET treatment across the US, EU4, UK ...
FGFR3-targeted therapies and the move of ADCs into muscle-invasive disease drive urothelial carcinoma growth across the US, EU4, UK and Japan.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Urothelial ...